Skip to main content



Clinical courses


Clinical courses

  • ERYTECH Sells U.S. Manufacturing Facility and Enters Long - Term Supply Agreement with Catalent

    ERYTECH Pharma a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.

  • Basilea reports preclinical data on oncology drug candidates BAL0891

    Basilea Pharmaceutica Ltd a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA.

  • Zymergen Advances Molecules for Prominent Malaria and COVID-19 Drug Targets for Further Testing

    Biotechnology company Zymergen is pleased to announce early results from its work on infectious disease, discovering hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • When to use or not use Antibiotics on your Skin

    Cold weather can be hard on your skin. When your skin becomes dry, as often happens in the winter, it can easily crack and bleed. When caring for a cut or other wound, it might seem logical to apply an antibiotic cream or ointment from the store to fight off germs and prevent infection. However, these antibiotic creams and ointments can irritate your skin even more and cause a painful and/or itchy rash, called contact dermatitis.

  • Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine

    Revive Therapeutics Ltd a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food and Drug Administratio has granted Orphan Drug Designation for Bucillamine for the prevention of ischemia–reperfusion injury during liver transplantation.

  • WHO grants prequalification of tocilizumab for patients with severe or critical COVID-19

    Roche announced that Actemra/RoActemra (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health.

  • Merck joins with artificial intelligence company, Quris for Clinical Safety Prediction

    Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, allowing Merck KGaA, Darmstadt, Germany to assess Quris’ BioAI safety prediction platform, comparing it to traditional in vitro and in vivo approaches.

  • FDA approves Enjaymo, first treatment for use in patients with cold agglutinin disease

    The U.S. Food and Drug Administration FDA has approved Enjaymo sutimlimab-jome to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease CAD. Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells hemolysis.

  • BioLife Sciences Inc Signs LOI with Health Box LLC Towards the 100% Acquisition of the Arizona

    BioLife Sciences is pleased to announce that it has entered into exclusive negotiations with Health Box LLC, an Arizona-based company which provides a diverse mix of advanced orthomolecular and natural health products founded in - extensive research focused on medicinal botanicals, micronutrients, dietary supplements, proprietary herbal blends, and apothecary style subscription services.

  • Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

    Marker Therapeutics, Inc a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product optimized for the treatment of patients with pancreatic cancer.

Subscribe to Globenewswire